These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17502555)

  • 1. Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies.
    Ballard CG; Chalmers KA; Todd C; McKeith IG; O'Brien JT; Wilcock G; Love S; Perry EK
    Neurology; 2007 May; 68(20):1726-9. PubMed ID: 17502555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis and treatment of dementia with Lewy bodies.
    Josif S; Graham K
    JAAPA; 2008 May; 21(5):22-6. PubMed ID: 18556885
    [No Abstract]   [Full Text] [Related]  

  • 3. Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis.
    Bhasin M; Rowan E; Edwards K; McKeith I
    Int J Geriatr Psychiatry; 2007 Sep; 22(9):890-5. PubMed ID: 17265415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and emerging pharmacological treatment options for dementia.
    Ringman JM; Cummings JL
    Behav Neurol; 2006; 17(1):5-16. PubMed ID: 16720956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergent complications following donepezil switchover to galantamine in three cases of dementia with Lewy bodies.
    Bhanji NH; Gauthier S
    J Neuropsychiatry Clin Neurosci; 2005; 17(4):552-5. PubMed ID: 16387998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Acetylcholinesterase inhibitors for dementia--an update].
    Anghelescu I; Heuser I
    MMW Fortschr Med; 2007 May; 149 Suppl 2():76-8. PubMed ID: 17724973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic treatment expectations in the management of dementia with Lewy bodies.
    Kaufer DI
    Dement Geriatr Cogn Disord; 2004; 17 Suppl 1():32-9. PubMed ID: 14676467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The acetylcholinesterase inhibitors for treatment of cognitive and behavioral symptoms in dementia with Lewy bodies.
    Simard M; van Reekum R
    J Neuropsychiatry Clin Neurosci; 2004; 16(4):409-25. PubMed ID: 15616167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
    Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
    J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successfully switching acetylcholinesterase inhibitor therapy in probable Lewy body dementia.
    Alwahhabi FK
    J Psychopharmacol; 2005 Mar; 19(2):214-6. PubMed ID: 15728444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Programs for continuing medical education: a session; 3. Dementia: diagnosis and therapy].
    Shoji M
    Nihon Naika Gakkai Zasshi; 2014 Mar; 103(3):630-6. PubMed ID: 24796129
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
    Darreh-Shori T; Hosseini SM; Nordberg A
    J Alzheimers Dis; 2014; 39(2):423-40. PubMed ID: 24217282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.
    Touchon J; Bergman H; Bullock R; Rapatz G; Nagel J; Lane R
    Curr Med Res Opin; 2006 Jan; 22(1):49-59. PubMed ID: 16393430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
    Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholinesterase inhibitors for dementia with Lewy bodies.
    Wild R; Pettit T; Burns A
    Cochrane Database Syst Rev; 2003; 2003(3):CD003672. PubMed ID: 12917981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
    Prescrire Int; 2007 Oct; 16(91):197-8. PubMed ID: 17926835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
    Robert P
    Curr Med Res Opin; 2002; 18(3):156-71. PubMed ID: 12094826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drug-cholinesterase-inhibitors persistence patterns in treated patients with dementia of Alzheimer type: retrospective comparative analysis of donepezil, rivastigmine and galantamine].
    Sicras A; Rejas-Gutiérrez J
    Rev Neurol; 2004 Aug 16-31; 39(4):312-6. PubMed ID: 15340887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].
    Sicras-Mainar A; Vergara J; Leon-Colombo T; Febrer L; Rejas-Gutierrez J
    Rev Neurol; 2006 Oct 16-31; 43(8):449-53. PubMed ID: 17033976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
    Rodda J; Morgan S; Walker Z
    Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.